X-linked Opitz G/BBBsyndrome is a congenital midline malformation syndrome characterized by facialanomalies, laryngo-tracheo-esophageal defects, and genitourinary abnormalities.Facial anomalies seen in X-linked Opitz G/BBB syndrome include ocularhypertelorism, prominent forehead, widow's peak, broad nasal bridge, andanteverted nares. Genitourinary abnormalities include hypospadias,cryptorchidism, and hypoplastic/bifid scrotum. The condition is geneticallyheterogeneous, as there is an autosomal dominant form as well.
Hypertelorismand hypospadias are the most frequent manifestations of X-linked Opitz G/BBBsyndrome, being present in almost all individuals. Developmental delay andmental retardation are observed in about 50% of affected males. Cleft lip and/or palate are present in approximately 50% of affected individuals. Other malformations present in fewer than 50% of individualsinclude congenital heart defects, imperforate or ectopic anus, and midline brain defects(Dandy-Walker malformation and agenesis or hypoplasia of the corpus callosumand/or cerebellar vermis). Monozygotic twinning is unusually frequent infamilies of individuals with X-linked Opitz G/BBB syndrome, and may be amanifestation of the defect; unusually severe cases with early lethality occuras twins. Wide clinical variability occurs even among members of the samefamily. Female carriers usually manifest only ocular hypertelorism. Theprevalence of X-linked Opitz G/BBB syndrome ranges from one in 50,000 to one in100,000 males.
Thediagnosis of X-linked Opitz G/BBB syndrome is established most often byclinical findings. MID1 (Xp22) is the only gene currently known to be associated with X-linked Opitz G/BBB syndrome. Sequence analysis of the MID1 gene detects mutations in15%-45% of males with clinically diagnosed Opitz G/BBB syndrome. Deletions andduplications in and of the MID1 genehave also been reported. The cohorts tested for MID1 mutations ofteninclude simplex cases (i.e., individuals with no family history of Opitz G/BBB syndrome), who therefore cannot be determined to have either theX-linked form or the autosomal dominant form. The detection rate is higher in individuals with clear X-linkedinheritance. De novo mutations havebeen reported.
For patients with suspected X-linked Opitz G/BBBsyndrome, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.
Click here for the GeneTests summary on this condition.
This test is indicated for:
- Confirmation of a clinical/biochemical diagnosis of X-linked Opitz G/BBB syndrome
- Carrier testing in adult females with a family history of X-linked Opitz G/BBB syndrome
Clinical Sensitivity: Sequence analysis of the MID1 gene detects mutations in 15%-45% of males with clinically diagnosed Opitz G/BBB syndrome. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's biochemical phenotype.
Analytical Sensitivity: ~99%
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.
Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
- Deletion/duplication analysis of the MID1 gene by CGH array is available for those individuals in whom sequence analysis is negative (ZD).
- A CGH array-based test for deletion/duplication analysis of 64 different X-linked intellectual disability genes is available (OL).
- Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to adult females who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.